Generic Name and Formulations:
Propylthiouracil 50mg; scored tabs; contains docusate sodium.
Various generic manufacturers
Indications for Propylthiouracil:
Give in 3 equally divided doses every 8hrs. Initially 300mg/day. Severe conditions: initially 400mg/day; max 900mg/day. Maintenance: 100–150mg/day.
Give in 3 equally divided doses every 8hrs. <6yrs: not recommended. ≥6yrs: initially 50mg/day; may upward titrate based on response, TSH, and free T4 levels.
Should be reserved for those intolerant to methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments. Risk of severe liver injury and acute liver failure. Monitor for signs of hepatic dysfunction esp. in the 1st 6 months of therapy; discontinue if occur and obtain LFTs and ALT/AST levels. Discontinue if agranulocytosis, aplastic anemia, ANCA-positive vasculitis, hepatitis, interstitial pneumonitis, fever, or exfoliative dermatitis is suspected. Monitor thyroid function periodically, prothrombin time esp. before surgical procedures. Pregnancy (Cat.D). Nursing mothers.
May potentiate anticoagulants. Caution with other drugs that may cause agranulocytosis. May need to reduce doses of beta-blockers, digitalis glycosides, theophylline at euthyroid state.
Rash, urticaria, GI upset, arthralgia, paresthesia, taste loss/perversion, hair loss, myalgia, headache, drowsiness, edema, vertigo, jaundice, blood dycrasias, lupus-like syndrome, drug fever, hepatitis, hypoprothrombinemia.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D